NASDAQ: LITSLite Strategy Inc Stock
$0.92+0.00 (+0%)
Updated Jun 17, 2026
LITS Price
$0.92
Fair Value Price
$2.70
Market Cap
$31.27M
52 Week Low
$0.69
52 Week High
$9.00
P/E
-0.46x
P/B
0.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$60.82M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$10M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LITS Overview
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LITS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LITS
Ranked#404 of 463
Ranked#404 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.93 | A | |
| $52.44 | A | |
| $16.14 | A |
Be the first to know about important LITS news, forecast changes, insider trades & much more!
LITS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LITS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LITS ($0.92) is undervalued by 66% relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LITS ($0.92) is significantly undervalued by 66% relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LITS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LITS due diligence checks available for Premium users.
Valuation
LITS fair value
Fair Value of LITS stock based on Discounted Cash Flow (DCF)
Price
$0.92
Fair Value
$2.70
Undervalued by
65.97%
LITS ($0.92) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LITS ($0.92) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LITS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LITS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.46x
Industry
14.91x
Market
12.4x
LITS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.55x
Industry
4.94x
LITS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LITS's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.7M
Profit Margin
0%
LITS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$57.8M
Liabilities
$952.0k
Debt to equity
0.02
LITS's short-term assets ($10.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LITS's short-term assets ($10.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LITS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LITS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$2.1M
Financing
-$1.8M
LITS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LITS vs Biotech Stocks
Lite Strategy Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.